Pipeline

A new generation of medicines.

OrphAI Therapeutics is advancing the following drugs into clinical trials/development: LAM-001 for Group 1 and Group 3 Pulmonary Hypertension (PH) and Bronchiolitis Obliterans Syndrome post lung transplant (BOS); AIT-102 for transcriptionally dysregulated cancers.

Phase 1

Phase 2

Program

Group 1 and Group 3 Pulmonary Hypertension

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

Program

Bronchiolitis Obliterans post Lung Transplant

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

Program

Transciptionally Dysregulated Tumors

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

Program

Amyotrophic Lateral Sclerosis

Hide Details

Preclinical

Phase 1

Phase 2

Phase 3

* Further development of AIT-101 is on hold pending non-dilutive funding